Treatment Response Assessment of Skeletal Metastases in Prostate Cancer with 18F-NaF PET/CT
To determine the utility of 18F-sodium fluoride positron emission tomography-computed tomography (18F-NaF PET/CT) in the imaging assessment of therapy response in men with osseous-only metastatic prostate cancer.
In this Institutional Review Board–approved single institution retrospective investigation, we evaluated 21 18F-NaF PET/CT scans performed in 14 patients with osseous metastatic disease from prostate cancer and no evidence of locally recurrent or soft-tissue metastatic disease who received chemohormonal therapy. Imaging-based qualitative and semi-quantitative parameters were defined and compared with changes in serum PSA level.
Qualitative and semi-quantitative image-based assessments demonstrated > 80% concordance with good correlation (SUVmax κ = 0.71, SUVavg κ = 0.62, SUVsum κ = 0.62). Moderate correlation (κ = 0.43) was found between SUVmax and PSA-based treatment response assessments. There was no statistically significant correlation between PSA-based disease progression and semi-quantitative parameters. Qualitative imaging assessment was moderately correlated (κ = 0.52) with PSA in distinguishing responders and non-responders.
18F-NaF PET/CT is complementary to biochemical monitoring in patients with bone-only metastases from prostate cancer which can be helpful in subsequent treatment management decisions.
Keywords18F-NaF PET/CT Prostate Cancer Metastasis Bone
positron emission tomography
We acknowledge National Institutes of Health grants R01-CA111613 (PI: H. Jadvar) and P30-CA014089 (USC Norris Comprehensive Cancer Center).
Compliance with Ethical Standards
Conflict of Interest
Erik M. Velez, Bhushan Desai, and Hossein Jadvar declare no conflicts of interest. There was no direct funding for this study.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 10.Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.Google Scholar
- 15.Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540–5.CrossRefGoogle Scholar
- 16.Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65:965–74.CrossRefGoogle Scholar
- 27.Jadvar H, Colletti PM. 18F-NaF/223RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome. Br J Radiol. 2018;91(1091):20170948.Google Scholar
- 28.Cook G Jr, Parker C, Chua S, Johnson B, Aksnes AK, Lweington VJ. 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res. 2011;1:4.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Harmon SA, Perk T, Lin C, Eickhoff J, Choyke PL, Dahut WL, et al. Quantitative assessment of early [18F]sodium fluoride positron emission tomography/computed tomography response to treatment in men with metastatic prostate cancer to bone. J Clin Oncol. 2017;35:2829–37.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Muzi M, O’Sullivan F, Muzi J, Mankofff D, Yu E. Whole body 18F-fluoride PET SUV imaging to monitor response to dasatinib therapy in castration-resistant prostate cancer bone metastases: secondary results from ACRIN 6687. J Nucl Med. 2018;59(suppl. 1):1465.Google Scholar
- 31.Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, et al. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687. J Nucl Med. 2015;56:354–60.CrossRefPubMedPubMedCentralGoogle Scholar